SCHEMBL19523219

SCHEMBL19523219

CC(=O)Nc1ccc(CNC2=Nc3ccccc3NC23CCSCC3)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.45
▸ RAB9A P51151 4/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ LMNA P02545 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ PKM P14618 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ MAPK8 P45983 3/20 0.37
▸ KDM1A O60341 1/20 0.37
▸ HPGD P15428 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ GPR39 O43194 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ PPID Q08752 1/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ NPC1 O15118 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19523225 0.90 PTPN1 (0.44) PTPN1RAB9AKMT2ALMNAALDH1A1
SCHEMBL19523102 0.90 PARP1 (0.41) PTPN1RAB9AKMT2AALDH1A1MEN1
SCHEMBL19523251 0.89 PTPN1 (0.43) PTPN1RAB9AKMT2ALMNAALDH1A1
SCHEMBL19523216 0.88 PTPN1 (0.42) PTPN1RAB9AKMT2ALMNAALDH1A1
SCHEMBL17757357 0.87 LMNA (0.31) RAB9ALMNAGAAMAPTKDM4E
SCHEMBL17992087 0.86 LMNA (0.33) LMNAHIF1A
SCHEMBL17757080 0.85 ACAT2 (0.38) RAB9AKMT2ALMNAMEN1PKM
SCHEMBL17757383 0.85 ALDH1A1 (0.39) KMT2ALMNAALDH1A1MEN1KDM1A
SCHEMBL19523172 0.84 CA1 (0.42) RAB9AKMT2ALMNAALDH1A1MEN1
SCHEMBL19523265 0.84 NPR1 (0.34) LMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE48992-E1 Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2022-03-29 — — US disclosed
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-05-12 — — US disclosed
US-10280179-B2 Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2019-05-07 — — US disclosed
US-20180065982-A1 SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) 2018-03-08 — — US disclosed
US-9802956-B2 Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MUNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) 2017-10-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 PTPN1 78/4885RAB9A 4069/4885KMT2A 4518/4885
US-10280179-B2 Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 PTPN1 126/4885RAB9A 2245/4885KMT2A 4285/4885
US-20180065982-A1 SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH AIFM2, BAD, AIFM1 PTPN1 126/4885RAB9A 2221/4885KMT2A 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback